Stock PSTV PLUS THERAPEUTICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Highlights Plus Therapeutics, Inc.

Equities

PSTV

US72941H5090

Market Closed - Nasdaq
Other stock markets
 01:30:00 15/05/2024 am IST 		5-day change 1st Jan Change
2.17 USD +0.46% Intraday chart for Plus Therapeutics, Inc. +1.88% +23.99%
09/05 Transcript : Plus Therapeutics, Inc. - Special Call
09/05 Plus Therapeutics, Inc. announced that it has received $7.262078 million in funding from Aigh Capital Management, LLC CI

Highlights

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Plus Therapeutics, Inc. Announces Validation & Clinical Implementation of Csf-01 Leptomeningeal Cancer Cell Diagnostic
CI
Plus Therapeutics Completes Dosing in Cohort 5 of ReSPECT-LM Phase 1 Trial of Rhenium Obisbemeda in Leptomeningeal Metastases
CI
Plus Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
CI
North American Morning Briefing : S&P 500 Futures -2-
DJ
Plus Therapeutics, Inc. Reports New Interim ReSPECT-GBM Phase 2 Trial Data at the Society for NeuroOncology Annual Meeting
CI
Plus Therapeutics, Inc. Provides Revenue Guidance for the Fourth Quarter of 2023 and Calendar Year of 2024
CI
Plus Therapeutics, Inc. announces an Equity Buyback for $0.5 million worth of its shares.
CI
Plus Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
CI
Plus Therapeutics, Inc. authorizes a Buyback Plan.
CI
Plus Therapeutics, Inc. Completes Dosing in Cohort 4 of ReSPECT-LM Phase 1 Clinical Trial of Rhenium Obisbemeda in Leptomeningeal Metastases
CI
Biocept Signs Non-Exclusive Licensing Agreement With Plus Therapeutics on CNSide Tumor Cell Platform
MT
Plus Therapeutics, Inc. Initiates Part B of ReSPECT-LM Phase 1/2a Trial for Leptomeningeal Metastase
CI
Tranche Update on Plus Therapeutics, Inc.'s Equity Buyback Plan announced on August 15, 2022.
CI
Tranche Update on Plus Therapeutics, Inc.'s Equity Buyback Plan announced on August 15, 2022.
CI
Plus Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023
CI
Plus Therapeutics, Inc.'s Equity Buyback announced on August 15, 2022 has expired with 0 shares, representing 0% for $0 million.
CI
Plus Therapeutics Says Leptomeningeal Metastases Phase 1 Trial of Rhenium Obisbemeda Showed Lower Tumor Cell Counts
MT
Plus Therapeutics, Inc. Reports Positive Interim Updates from Two Respect Clinical Trials at SNMMI Annual Meeting
CI
Reverse Split: 1 of 15
FA
Reverse Split: 1 of 15
FA
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. PSTV Stock
  4. News Plus Therapeutics, Inc.
  5. Highlights
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
SIGN UP NOW